Key Highlights: Implications: Obeda gives Dr. Reddy’s a second GLP‑1 foothold in India, but this time in the much bigger day‑to‑day diabetes market, not just injectable semaglutide. Because it ...
Key Highlights: Implications: Emcure is effectively repositioning Poviztra as a mass‑market GLP‑1 for obesity in India, using a steep 55% entry‑dose cut (now ₹3,999/mon...
Key Highlights: Implications: Usema adds another early DCGI‑approved semaglutide brand to India’s GLP‑1 wave, giving USV a bioequivalent, locally manufactured injectable that fits neatly i...
Key Highlights: Implications: Obeda’s Day‑1 launch with DCGI approval and head‑to‑head Phase III data positions Dr. Reddy’s as a clinically credible, early GLP‑1 player, even at a higher ~...
Key Highlights: Implications: By pairing one of the lowest weekly price points in the GLP‑1 segment (₹325–₹440) with a vial‑plus‑pen strategy, Glenmark is clearly targeting early initiatio...
Key Highlights: Implications: Zydus is differentiating in a crowded GLP‑1 space with a single reusable multi‑dose pen and 15 mg/3 mL cartridge, simplifying titration and potentia...
Key Highlights: Implications: By pricing its once‑weekly semaglutide at around ₹450 per week via a pre‑filled disposable pen, Alkem is positioning one of the lowest‑cost GLP‑1 op...
Key Highlights: Implications: By launching semaglutide under two differentiated brands with full dose coverage and price points 60%+ below innovator levels, Sun is set to rapidly expand ac...
Key Highlights: Implications: With Sundae vials starting at ₹1,290 per month and a pen device to follow, Eris is leveraging Natco’s low‑cost manufacturing while using its strong diab...
Key Highlights: Implications: By launching Day‑1 multi‑dose vials at ₹1,290–₹1,750 per month and claiming 70–90% discounts vs pens and innovator brands, Natco is setting the floor on...
